Nabriva Therapeutics

Company snapshot

Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of novel antibiotics to treat serious infections. Nabriva Therapeutics has two products: Xenleta (lefamulin), recently approved by the FDA for both Oral and IV use and CONTEPO (fosfomycin) for injection, we submitted an NDA for CONTEPO, a potential first-in-class epoxide antibiotic in the United States

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Nabriva Therapeutics. Not investment advice.

• What is Nabriva Therapeutics?

  Nabriva Therapeutics Ireland is a pharma organization headquartered in IE. Primary therapeutic focus areas include Community Acquired Pneumonia. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTria

• Is Nabriva Therapeutics publicly traded?

  Nabriva Therapeutics appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Nabriva Therapeutics develop or market?

  We link 1 drug profile(s) where Nabriva Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/nabriva-therapeutics-ireland-dac#company-drugs.

• What are the latest developments for Nabriva Therapeutics?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Nabriva Therapeutics focus on?

  Nabriva Therapeutics focuses on Community Acquired Pneumonia based on our analysis of their pipeline programs and drug development activities.